Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $8 from $13 and keeps an Equal Weight rating on the shares. Sentiment into Q3 earnings is “broadly cautious” on the Life Science Tools & Diagnostics group given tight customer budgets, destocking and China issues, the analyst tells investors in a group preview note. Stocks where 2024 estimates have “corrected sufficiently” and “bake in a metered recovery” could catch a bid into year-end, the analyst added, pointing to Thermo Fisher (TMO) and Natera (NTRA) as top picks among the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CTKB:
- Cytek Biosciences price target lowered to $10 from $15 at Piper Sandler
- Cytek Biosciences achieves ISO 13485 Certification at headquarters
- Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters
- Cytek Biosciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
- Cytek Biosciences to highlight cell analysis solutions at clinical conferences